Ginkgo Bioworks Holdings, Inc. (DNA)
Market Cap | 2.30B |
Revenue (ttm) | 251.46M |
Net Income (ttm) | -892.87M |
Shares Out | 2.15B |
EPS (ttm) | -0.46 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 16,093,179 |
Open | 1.070 |
Previous Close | 1.070 |
Day's Range | 1.060 - 1.130 |
52-Week Range | 1.030 - 2.545 |
Beta | 1.42 |
Analysts | Hold |
Price Target | 2.20 (+100.0%) |
Earnings Date | May 8, 2024 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more]
Financial Performance
In 2023, DNA's revenue was $251.46 million, a decrease of -47.36% compared to the previous year's $477.71 million. Losses were -$892.87 million, -57.58% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for DNA stock is "Hold." The 12-month stock price forecast is $2.2, which is an increase of 100.00% from the latest price.
News
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production
The partners will work to optimize AQUA Cultured Foods' fermentation technology and advance the development and production of AQUA's 100% fish-free products that emulate the look, feel, and taste of f...
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins
Imagindairy and Ginkgo will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to economically produce non-whey dairy proteins for the food indus...
CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago
The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travele...
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
$251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and con...
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks' New Technology Network
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- #Celltherapy--bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell p...
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction ...
Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, ...
Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences ,...
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Rever...
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing Ginkgo plans to integrate the techn...
Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones
The center will be a first of its-kind collection and analysis center for data gathered through Ginkgo's pathogen monitoring network DOHA, Qatar , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: ...
Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference
BOSTON , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, i...
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024 BOSTON , Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cel...
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
BOSTON and LEXINGTON, Mass. , Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Progra...
House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
Members of Congress visited Ginkgo's Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in ...
Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval
KETCHUM, Idaho , Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United ...
Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains
This first milestone has made the full color palette of the yellow-to-purple spectrum accessible for Phytolon's food colors and has further established a unique and cost-efficient offering for the foo...
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO , Jan. 15, 2024 /PRNewswire/ -- Concentr...
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees ope...
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
BOSTON , Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advis...
Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform
Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwide BOSTON , Jan. 4, 2024 /PRNewswire/ -- Ginkgo ...
Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is...
OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product
OneOne is a French biotech startup developing a comprehensive suite of agricultural microbial solutions Ginkgo will support OneOne in its agricultural biologicals and synthetic biology R&D Ginkgo will...
U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions
Algae-based biotechnology can be used to drive forward clean energy solutions, such as sustainable aviation fuel, yet scaling algal biotechnologies for such purposes faces major barriers The DOE has a...
GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals'
GreenLab is creating an enzymatic solution — to be grown and scaled within corn plants — to degrade PFAS, often called "forever chemicals," a major health and environmental concern Ginkgo has been tap...